MA50102A - Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques - Google Patents

Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques

Info

Publication number
MA50102A
MA50102A MA050102A MA50102A MA50102A MA 50102 A MA50102 A MA 50102A MA 050102 A MA050102 A MA 050102A MA 50102 A MA50102 A MA 50102A MA 50102 A MA50102 A MA 50102A
Authority
MA
Morocco
Prior art keywords
compositions
manufacturing
methods
bispecific antibodies
bispecific
Prior art date
Application number
MA050102A
Other languages
English (en)
Inventor
Sanchita Bhatnagar
Jogender Tushir-Singh
Original Assignee
Univ Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Patent Foundation filed Critical Univ Virginia Patent Foundation
Publication of MA50102A publication Critical patent/MA50102A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA050102A 2017-11-14 2018-11-13 Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques MA50102A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762585647P 2017-11-14 2017-11-14

Publications (1)

Publication Number Publication Date
MA50102A true MA50102A (fr) 2020-07-15

Family

ID=66539870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050102A MA50102A (fr) 2017-11-14 2018-11-13 Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques

Country Status (4)

Country Link
US (1) US12545739B2 (fr)
EP (1) EP3710482A4 (fr)
MA (1) MA50102A (fr)
WO (1) WO2019099374A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3710482A4 (fr) 2017-11-14 2021-08-18 University Of Virginia Patent Foundation Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
US20220411508A1 (en) * 2019-09-09 2022-12-29 The Regents Of The University Of California Compositions and methods for making and using multispecific antibodies
US20250376532A1 (en) * 2021-08-20 2025-12-11 University Of Virginia Patent Foundation Strategy for highly superior dr5 activation including in tumors and cancers
AU2023375570A1 (en) 2022-11-10 2025-06-12 Immuvia Inc Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL84285A (en) 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5292867A (en) 1988-11-16 1994-03-08 Tanox Biosystems, Inc. Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin
IL94872A (en) 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same
US5081235A (en) 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
US5075431A (en) 1989-07-26 1991-12-24 City Of Hope Chimeric anti-CEA antibody
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
US5339232A (en) 1993-01-12 1994-08-16 Lin Te H Miniature light set
US5472693A (en) 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6927286B1 (en) * 1999-01-06 2005-08-09 The Regents Of The University Of California Bleomycin gene cluster components and their uses
CA2773515C (fr) 2009-09-29 2015-04-28 Roche Glycart Ag Anticorps agonistes bispecifiques du recepteur de mort
SG189835A1 (en) 2010-10-20 2013-06-28 Oxford Biotherapeutics Ltd Antibodies
WO2012061759A2 (fr) 2010-11-05 2012-05-10 Morphotek Inc. Récepteur alpha de folate à titre de marqueur diagnostique et pronostique des cancers exprimant un récepteur alpha de folate
CN104093744A (zh) 2011-10-11 2014-10-08 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
US9836150B2 (en) * 2012-11-20 2017-12-05 Immersion Corporation System and method for feedforward and feedback with haptic effects
FR3000815B1 (fr) * 2013-01-07 2019-10-11 Stmicroelectronics (Rousset) Sas Regulateur d'alimentation d'un circuit integre
WO2014109927A1 (fr) * 2013-01-11 2014-07-17 The Regents Of The University Of Michigan Synthèse et isolement d'un dendrimère à base de systèmes d'imagerie
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US20140363454A1 (en) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
WO2014197854A1 (fr) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Nouveaux lieurs pour conjugués anticorps-médicament et composés connexes, compositions, et procédés d'utilisation
WO2014197866A1 (fr) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anticorps modifiés et composés associés, compositions et procédés d'utilisation
US20160311921A1 (en) 2013-06-20 2016-10-27 Morphotek ,Inc. Methods for treatment of ovarian cancer
WO2016007950A1 (fr) 2014-07-11 2016-01-14 Vanderbilt Universtiy Appareil et procédés pour sonder un matériau en fonction de la profondeur au moyen de la génération de deuxième harmonique dépendante de la profondeur
EP3209334A2 (fr) * 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Nouveaux conjugués anticorps-médicament et composés, compositions et procédés d'utilisation s'y rapportant
RU2753902C2 (ru) * 2014-11-20 2021-08-24 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
WO2017093448A1 (fr) 2015-12-01 2017-06-08 Genmab B.V. Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
KR20250036943A (ko) * 2016-08-02 2025-03-14 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
PL3606955T3 (pl) 2017-04-05 2025-02-24 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3
EP3710482A4 (fr) 2017-11-14 2021-08-18 University Of Virginia Patent Foundation Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
EP3980080A1 (fr) * 2019-06-10 2022-04-13 Sutro Biopharma, Inc. Conjugués anticorps-médicament immunomodulateurs et utilisations associées
WO2021150770A1 (fr) 2020-01-21 2021-07-29 University Of Virginia Patent Foundation Trim37 oncogène est un pilote épigénétique pouvant être ciblé de métastase et lie la chimiorésistance et le devenir métastatique dans le cancer du sein triple-négatif
DE102021208038A1 (de) * 2021-07-26 2023-01-26 Mahle International Gmbh Verdampfer
US20250376532A1 (en) * 2021-08-20 2025-12-11 University Of Virginia Patent Foundation Strategy for highly superior dr5 activation including in tumors and cancers

Also Published As

Publication number Publication date
US12545739B2 (en) 2026-02-10
WO2019099374A3 (fr) 2020-04-02
WO2019099374A2 (fr) 2019-05-23
EP3710482A2 (fr) 2020-09-23
US20200283537A1 (en) 2020-09-10
EP3710482A4 (fr) 2021-08-18

Similar Documents

Publication Publication Date Title
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA49726A (fr) Formulation d'anticorps anti-cgrp
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
EP3728323A4 (fr) Anticorps anti-fzd et méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d'utilisation
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
MA51417A (fr) Constructions d'anticorps bispécifiques dirigés contre muc17 et cd3
EP3538153A4 (fr) Anticorps anti-cd46 et méthodes d'utilisation
EP3684369A4 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
MA50958A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
EP3710589A4 (fr) Anticorps anti-c1s et procédés d'utilisation